A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine

Completed · Phase 3

Conditions studied: Migraine, Migraine With Aura, Migraine Without Aura

In brief

Study STS101-003 is a multi-center, multiple dose (PRN), open-label, 12-month study to evaluate the safety and tolerability of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine.

Key facts

Study ID
NCT04406649
Run by
Satsuma Pharmaceuticals, Inc.
People needed
482
Starts
2020-09-14
Expected to finish
2023-01-16
Last updated by the study team
2023-07-03

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.